(Q37818336)

23 August 2017

1 reference

title

Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients (English)

1 reference

23 August 2017

1 reference

1 reference

1 reference

Tabinda Burney

1

1 reference

PubMed ID

21143041

23 August 2017

Geoffrey Dusheiko

series ordinal

2

1 reference

23 August 2017

14 December 2010

1 reference

Expert Review of Anti-infective Therapy

23 August 2017

1 reference

23 August 2017

9

1 reference

23 August 2017

151-160

1 reference

23 August 2017

2

1 reference

Global epidemiology of hepatitis C virus infection

23 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

The epidemiology of hepatitis C infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Worldwide mortality from cirrhosis: an update to 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

The healthcare burden imposed by liver disease in aging Baby Boomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Epidemiology of hepatitis B in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Outcome of hospital care of liver disease associated with hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Peginterferon and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Hepatitis C virus: a critical appraisal of approaches to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Expert opinion on the treatment of patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

The hepatitis C virus life cycle as a target for new antiviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

The way forward in HCV treatment--finding the right path

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Future therapies for hepatitis C: where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Hepatitis C Virus NS3/4A Protease Inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

A step forward in therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Hepatitis C drug development at a crossroads

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Comment on the PROVE1 and PROVE2 clinical trials: "I was taking a picture of Rapid Virological Response with telaprevir, but the background is unfocused!".

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Treatment of hepatitis C in 2011: what can we expect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Excitement grows for potential revolution in hepatitis C virus treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

STAT-C: a full revolution or just a step forward?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Resistance to direct antiviral agents in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Characterization of resistance mutations against HCV ketoamide protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

21 January 2018

Emerging antiviral drugs

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.153

21 January 2018

Identifiers

DOI

10.1586/ERI.10.153

1 reference

23 August 2017

1 reference

PubMed ID

21143041